There is no simple and reliable way to test for<unk>  in women who do not have any signs or symptoms. Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks. The Pap test does not screen for<unk> .<unk>  is usually only palpable in advanced stages. Screening is not recommended using CA-125 measurements, HE4 levels, ultrasound, or adnexal palpation in women who are at average risk. Risk of developing<unk>  in those with genetic factors can be reduced. Those with a genetic predisposition may benefit from screening. This high risk group has benefited with earlier detection.<unk>  has low prevalence, even in the high-risk group of women from the ages of 50 to 60 (about one in 2000), and screening of women with average risk is more likely to give ambiguous results than detect a problem that requires treatment. Because ambiguous results are more likely than detection of a treatable problem, and because the usual response to ambiguous results is invasive interventions, in women of average risk, the potential harms of having screening without an indication outweigh the potential benefits. The purpose of screening is to diagnose<unk>  at an early stage when it is more likely to be treated successfully. Screening with transvaginal ultrasound, pelvic examination, and CA-125 levels can be used instead of preventive surgery in women who have BRCA1 or BRCA2 mutations. This strategy has shown some success. Screening for CA125, a chemical released by<unk>  tumours, with follow-up using ultrasound, was shown to be ineffective in reducing mortality in a large-scale UK study.
Ovarian cancer
Uterine fibroid  s  1
Breast cancer
Uterine cancer
Cervical cancer
Endometrial cancer
Ovarian cyst
Fallopian tube cancer